Blocking a protein could help overcome cancer resistance to PARP inhibitors

Researchers have found that blocking a specific protein could increase tumor sensitivity to treatment with PARP inhibitors. Their work suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers.

Quelle: Sciencedaily

Method to ‚turn off‘ mutated melanoma

Melanoma is the deadliest form of skin cancer and notorious for its resistance to conventional chemotherapy. Approximately 25 percent of melanoma is driven by oncogenic mutations in the NRAS gene, making it a very attractive therapeutic target. However, despite decades of research, no effective therapies targeting NRAS have been forthcoming.

Quelle: Sciencedaily

An errant editing enzyme promotes tumor suppressor loss and leukemia propagation

Researchers have found a stem cell enzyme copy edits more than 20 tumor types, providing new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation. (Mehr in: Cancer News — ScienceDaily)

Sulfate Helps Plants Cope With Water Scarcity

Plants absorb the mineral sulfate from groundwater. An international research team led by scientists from Heidelberg University has uncovered how sulfate controls the production of the drought stress hormone ABA in plants and thus contributes to their drought-resistance. These findings improve scientists‘ understanding of how the drought-stress signal travels from the roots to the leaves. The studies in Heidelberg were carried out at the Centre for Organismal Studies (COS). (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)

Two ways cancer resists treatment are actually connected, with one activating the other

Researcher shows the two most common means of resistance to BRAF and MEK inhibitors are actually connected processes and can be targeted by other therapies. (Mehr in: Cancer News — ScienceDaily)

Potential seen for tailoring treatment for acute myeloid leukemia

Rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia. Research on the differing drug response patterns of leukemia stem cells and blasts may show why some attempts to treat are not successful and why some patients relapse. (Mehr in: Cancer News — ScienceDaily)

New drug combination could be more effective against melanoma

A new study suggests that combining kinase inhibitors with experimental drugs known as ribonucleases could lead to better results. In tests with human cancer cells, the researchers found that the two drugs given together kill cells much more effectively than either drug does on its own. The combination could also help to prevent tumors from developing drug resistance. (Mehr in: Cancer News — ScienceDaily)

Danger in the Desert

Mutations of the MERS virus contribute to its resistance against the defenses of the immune system (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)

Dodging antibiotic resistance by curbing bacterial evolution

Lowering mutation rates in harmful bacteria might be an as yet untried way to hinder the emergence of antimicrobial pathogens. One target for drug development might be a protein factor, DNA translocase Mfd, that enables bacteria to evolve rapidly by promoting mutations in many different bacterial species. This action speeds antibiotic resistance, including multi-drug resistance. Working on drugs to block Mfd and similar factors could be a revolutionary strategy to address the worldwide crisis of treatment-resistant infectious diseases. (Mehr in: Cancer News — ScienceDaily)

Rainforest vine compound starves pancreatic cancer cells

Pancreatic cancer cells are known for their ability to thrive under extreme conditions of low nutrients and oxygen, a trait known in the cancer field as ‚austerity.‘ The cells‘ remarkable resistance to starvation is one reason why pancreatic cancer is so deadly. Now researchers have identified a compound from a Congolese plant that has strong “antiausterity“ potential, making pancreatic cancer cells susceptible to nutrient starvation. (Mehr in: Cancer News — ScienceDaily)

New drug candidates reverse drug resistance in multiple myeloma in preclinical models

A new strategy to enhance the activity of proteasome inhibitors (PIs), which are standard-of-care agents in the treatment of multiple myeloma (MM), was recently reported. The study introduces a new drug candidate that overcomes PI resistance in cultured cells and extends survival in mouse models of MM. (Mehr in: Cancer News — ScienceDaily)

Testing cells for cancer drug resistance

Biophysicists have demonstrated that Raman microscopy can be used to detect the resistance of tumor cells to cancer drugs. Unlike conventional approaches, this method does not require any antibodies or markers. It detects the response of cells to administered drugs and therefore could determine the effect of drugs in preclinical studies. (Mehr in: Cancer News — ScienceDaily)

Mechanism of resistance to novel targeted therapy for ovarian cancer identified

Scientists have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene. (Mehr in: Cancer News — ScienceDaily)

Could less deadly therapies be a better way to keep cancer in check?

While many cancer therapies initially can be very successful, tumors often return and spread when remaining cancer cells develop resistance to treatment. To combat this tendency, cancer researchers could take a lesson from our own immune system and explore ’natural adaptive therapies,‘ according to a new article. (Mehr in: Cancer News — ScienceDaily)

Lung cancer drug could be repurposed to target ‚zombie‘ proteins linked to leukemia

A new study highlights how a clinically approved lung cancer drug could potentially be ‚repurposed‘ to design new treatments for future cancer therapies. The research focuses on a protein called TRIB2, which is linked to promoting survival and drug resistance in solid tumors and blood cancers and is therefore of particular interest as a therapeutic target. (Mehr in: Cancer News — ScienceDaily)

New drug blocks pancreatic cancer growth in mice, study finds

A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a new study. The study also demonstrated in mice that the drug, Metavert, may prevent patients from developing a resistance to currently used pancreatic cancer chemotherapies. (Mehr in: Cancer News — ScienceDaily)

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

Scientists have found a way to boost the efficacy of the antimalarial drug artemesinin with the help of chemotherapy medicines. Artemisinin works through a ‚double whammy‘ attack on the deadly parasite. The drug damages proteins in malaria parasites and clogs the parasite’s waste disposal system, known as the proteasome, which chemo can target. (Mehr in: Cancer News — ScienceDaily)

Cellular memory outwits pathogens

Study by Kiel Evolution Center proves effectiveness of sequential antibiotic treatment against the pathogen Pseudomonas aeruginosa

The World Health Organization (WHO) warns that seemingly harmless bacterial infections could develop into one of the leading causes of death in the next few years, particularly in the industrialised countries. This dramatic threat arose because, in many cases, the antibiotics that have been prescribed for decades as a standard treatment have become ineffective due to increasing resistance, and this trend continues to gather pace. (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)

How infectious bacteria hibernate through treatment

Tübingen researchers find that bacteria may opt for persistence as well as resistance to antibiotics (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)

Hormone therapy can make prostate cancer worse, study finds

Scientists have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. (Mehr in: Cancer News — ScienceDaily)

Study of rare cancer yields therapeutic clues to combat drug resistance

The team set out to explore cancer drivers that allow NUT midline carcinoma — a rare, aggressive cancer that can arise in multiple organs — to become impervious to drugs. Their results may apply to several forms of cancer fueled by the same mutated driver gene, and their approach may be applicable to other types of cancer whose genomes have been sequenced. (Mehr in: Cancer News — ScienceDaily)

Investigating treatment resistance in cancer

Melanoma and liver cancer are becoming more widespread in Europe and the US. Whilst both diseases progress very differently, they are among the types of cancer which are most likely to be fatal in the Western world. Three groups of researchers from the Institute of Biochemistry at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have discovered a mechanism used to steer the growth of the cancer cells in both types of cancer, a discovery which is significant for future treatment strategies. The researchers’ work has now been recognised with a prestigious award from the Deutsche Leberstiftung (German Liver Foundation) for a groundbreaking publication in the field of liver research. (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)

Epigenetic reason for drug resistance discovered in a deadly melanoma

Researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a new study. (Mehr in: Cancer News — ScienceDaily)

Keeping cancer out of breath blocks drug resistance

Chemists have demonstrated a new approach to blocking cancer-drug resistance that they believe could be applied to any type of cancer. In a dramatic result, the approach — which involves chemically combining two existing drugs in a new way — produced 50 percent smaller tumors in mice compared with a traditional treatment with the same drugs given separately. (Mehr in: Cancer News — ScienceDaily)

Protein discovery may explain why patients develop resistance to new anti-cancer drugs

Researchers have identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication. (Mehr in: Cancer News — ScienceDaily)